Michael Becker joined Relmada Therapeutics Inc. in November 2014, and currently serves as the company’s vice president of finance and corporate development. Mr. Becker brings more than 20 years of experience as a C-level industry executive and Wall Street securities analyst. Most recently, he was founder and president of the consulting firm MDB Communications LLC. In this position, he acted as a strategic advisor and partner servicing the life sciences industry by providing a full range of investor relations and public relations services to enhance client visibility and branding. Mr. Becker previously served as president, chief executive officer and member of the board of directors for publicly traded biotechnology companies including commercial-stage Cytogen Corp. (acquired by EUSA Pharma). He held positions of increasing responsibility prior to being appointed president and CEO of Cytogen in 2002, including vice president of business development, industry and investor relations, and CEO of AxCell Biosciences, a subsidiary of Cytogen. Prior to his industry career, Mr. Becker spent nine years in the financial services industry, which includes positions at Wayne Hummer Investments LLC, Kidder, Peabody & Co., Gruntal & Co., and Kemper Securities. He completed coursework in political science at DePaul University, and received an associate of science degree from the Art Institute of Pittsburgh.